Recently, it was reported that RUNX1 mutation is associated with rapid progression of low-risk MDS and that mutations in this gene in CD34+ cells from low-risk MDS patients result in dysregulated DNA damage repair and cellular senescence [78]. The gene discussed is RUNX1; the disease is myelodysplastic syndrome.